Morepen Laboratories files its first US ANDA for sitagliptin tablets
The filing for sitagliptin tablets in three strengths marks Morepen's entry into integrated finished-dose development and regulatory filings in the US market
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.